TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16086933

Group type: EXPERIMENTAL
Intervention: LAA occlusion using sutures
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: LAA occlusion using a stapler
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (no LAA occlusion)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Postoperative follow-up
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Surgeon experience
Number of subjects: 77
Study: 12383044

Group type: EXPERIMENTAL
Intervention: Fondaparinux sodium 10mg subcutaneously for 7 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Digoxin 0.25mg orally for 7 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Coadministration of fondaparinux sodium 10mg and digoxin 0.25mg
Number of subjects: 24
Study: 10597550

Group type: EXPERIMENTAL
Intervention: Sevoflurane 7% followed by maintenance with 1.7%
Number of subjects: 120

Group type: COMPARATOR
Intervention: Propofol 3 mg.kg‐1 followed by a maintenance infusion of 5 mg.kg‐1.h‐1
Number of subjects: 120
Study: 8567345

Group type: EXPERIMENTAL
Intervention: Preoperative concomitant radiochemotherapy (two courses of 18.5 Gy in five fractions, continuous infusion of 5-FU 800 mg/m2 days 1-5 and cisplatinum 70 mg/m2 day 2)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Preoperative concomitant radiochemotherapy
Number of subjects: 56
Study: 1824249

Group type: EXPERIMENTAL
Intervention: Cytarabine (Ara‐C) 100 mg/m2 (A100)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Cytarabine (Ara‐C) 200 mg/m2 (A200)
Number of subjects: 326
Study: 6419632

Group type: EXPERIMENTAL
Intervention: Spinal analgesia with sedation
Number of subjects: 60

Group type: COMPARATOR
Intervention: General anaesthesia with controlled ventilation
Number of subjects: 60
Study: 31558596

Group type: EXPERIMENTAL
Intervention: Automated interactive voice messages promoting contraceptive use (at least 11 messages over 4 months)
Number of subjects: 969

Group type: COMPARATOR
Intervention: Control group (no messages)
Number of subjects: 969

Group type: EXPERIMENTAL
Intervention: Automated interactive voice messages promoting contraceptive use
Number of subjects: 969
Study: 29525617

Group type: EXPERIMENTAL
Intervention: Oral acetazolamide administered 1 hour preoperatively
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Oral acetazolamide administered 3 hours postoperatively
Number of subjects: 96

Group type: COMPARATOR
Intervention: No administration of acetazolamide
Number of subjects: 96
Study: 26340097

Group type: EXPERIMENTAL
Intervention: Oral solifenacin succinate 5 mg/day
Number of subjects: 80

Group type: COMPARATOR
Intervention: Healthy female subjects (control group)
Number of subjects: 80
Study: 24196467

Group type: EXPERIMENTAL
Intervention: Topical (intra-articular) tranexamic acid
Number of subjects: 161
Study: 21256649

Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray (3 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 20
Study: 19194326

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI, 5-10 minutes) + Internet program
Number of subjects: 84

Group type: COMPARATOR
Intervention: Brief Advice (BA, 1-2 minutes) + Internet program
Number of subjects: 84
Study: 16481638

Group type: EXPERIMENTAL
Intervention: High-dose adjuvant interferon alfa-2b
Number of subjects: 200
Study: 15215813

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 80 mg
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 5 mg
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 5 mg and 10 mg
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (all doses)
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 383

Group type: COMPARATOR
Intervention: Atorvastatin
Number of subjects: 383
Study: 10974371

Group type: EXPERIMENTAL
Intervention: Combination antiretroviral treatment
Number of subjects: 45
Study: 9314129

Group type: EXPERIMENTAL
Intervention: Primary sclerosing cholangitis
Number of subjects: 134

Group type: COMPARATOR
Intervention: No primary sclerosing cholangitis
Number of subjects: 134
Study: 8136092

Group type: EXPERIMENTAL
Intervention: Captopril treatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 10
Study: 3720279

Group type: EXPERIMENTAL
Intervention: Token financial incentive of two cents for returning the questionnaire
Number of subjects: 0

Group type: COMPARATOR
Intervention: No token financial incentive
Number of subjects: 0
Study: 31184579

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin 100 mg
Number of subjects: 0
Study: 29149618

Group type: EXPERIMENTAL
Intervention: Patient-centred, empowerment-based self-management programme (6 weeks)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Patient-centred, empowerment-based self-management programme
Number of subjects: 242

Group type: COMPARATOR
Intervention: Attentional control (health education classes and post-discharge follow-up)
Number of subjects: 242
Study: 27997673

Group type: EXPERIMENTAL
Intervention: Genium knee
Number of subjects: 25

Group type: COMPARATOR
Intervention: C-Leg
Number of subjects: 25
Study: 25518030

Group type: EXPERIMENTAL
Intervention: Postoperative oxygen supplementation via nasal catheter
Number of subjects: 109

Group type: COMPARATOR
Intervention: No postoperative oxygen supplementation
Number of subjects: 109
Study: 22595363

Group type: EXPERIMENTAL
Intervention: Galantamine (8 mg/day for 4 weeks, then 16 mg/day for 12 weeks)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study: 20526694

Group type: EXPERIMENTAL
Intervention: Bariatric group (B)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 20
Study: 18955453

Group type: EXPERIMENTAL
Intervention: Cooked diet (no raw fruits or vegetables)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Raw diet (fresh fruit and fresh vegetables)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Cooked diet
Number of subjects: 153

Group type: COMPARATOR
Intervention: Raw diet
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 153
Study: 19368781

Group type: EXPERIMENTAL
Intervention: DTPa vaccine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: dTpa vaccine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Hepatitis A control vaccine
Number of subjects: 100
Study: 15688965

Group type: EXPERIMENTAL
Intervention: Manual Stimulation Distraction Device (MSDD)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No Manual Stimulation Distraction Device (Control)
Number of subjects: 100
Study: 12413615

Group type: EXPERIMENTAL
Intervention: 10 mg of mifepristone alone (Group 1)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: 20 mg of tamoxifen with 10 mg of mifepristone (Group 2)
Number of subjects: 400
Study: 9042043

Group type: EXPERIMENTAL
Intervention: Budesonide via Turbuhaler (0.4, 0.8, 1.6, and 2.4 mg/day for 2 weeks)
Number of subjects: 58
Study: 7930659

Group type: EXPERIMENTAL
Intervention: 75 mg of aspirin per day
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control (no aspirin)
Number of subjects: 46
Study: 3251510

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 6

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 11120898

Group type: EXPERIMENTAL
Intervention: Induced sputum (3% NaCl, 20 minutes)
Number of subjects: 20
Study: 31350828

Group type: EXPERIMENTAL
Intervention: Early intensive antihypertensive treatment (100 mg urapidil and 30 mL of 0.9% sodium chloride after initial 25 mg urapidil injection)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Early intensive antihypertensive treatment
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group (25 mg urapidil injection)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 121
Study: 29322620

Group type: EXPERIMENTAL
Intervention: Spent hops-rice protein matrix preparation
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control spent hops preparation
Number of subjects: 6
Study: 26597151

Group type: EXPERIMENTAL
Intervention: Low-dose lipopolysaccharide (LPS) 0.4 ng/kg
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 24652018

Group type: EXPERIMENTAL
Intervention: Self-retaining barbed sutures (SRBS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional sutures
Number of subjects: 50
Study: 22703720

Group type: EXPERIMENTAL
Intervention: Emotion‐recognition‐training (ERT)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Treatment‐as‐usual (TAU)
Number of subjects: 195
Study: 21156883

Group type: EXPERIMENTAL
Intervention: Insulin initiation
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Insulin therapy
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Concomitant use of oral antihyperglycemic agents
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Sulfonylurea use
Number of subjects: 379
Study: 17389205

Group type: EXPERIMENTAL
Intervention: Topical papaverine application at room temperature
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Topical heated papaverine (at 37 degrees C) application
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Internal thoracic artery pedicle storage in normothermic conditions
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Pedicle storage in normothermic conditions combined with topical papaverine application
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Pedicle storage in normothermic conditions combined with topical heated papaverine application
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no treatment, stored at room temperature)
Number of subjects: 120
Study: 15647189

Group type: EXPERIMENTAL
Intervention: Synbiotic therapy (Bifidobacterium longum/Synergy 1)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 12390566

Group type: EXPERIMENTAL
Intervention: Electrically active toothbrush
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control brush (Butler GUM 309)
Number of subjects: 66
Study: 9950310

Group type: EXPERIMENTAL
Intervention: Multiple linear regression model (MR)
Number of subjects: 2144

Group type: EXPERIMENTAL
Intervention: Artificial neural network (ANN)
Number of subjects: 2144
Study: 7598144

Group type: EXPERIMENTAL
Intervention: PCR positive patients (n=14 of 76, 18.4%)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Patients with systemic symptoms (n=33)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Patients with multiple skin lesions (n=16)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Patients with a higher total number of symptoms (median 2.5 in PCR-positive patients)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Asymptomatic patients with single erythema migrans lesions (n=42)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Overall PCR detection of Borrelia burgdorferi
Number of subjects: 105
Study: 2090821

Group type: EXPERIMENTAL
Intervention: High frequency TNS (100 Hz)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Low frequency TNS (2 Hz)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo TNS
Number of subjects: 19
Study: 835319

Group type: EXPERIMENTAL
Intervention: Early mobilisation programme (B)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional mobilisation (A)
Number of subjects: 200
Study: 30497110

Group type: EXPERIMENTAL
Intervention: Data submitted by the treating surgeon for peer review
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Thromboembolism deterrent stockings
Number of subjects: 629
Study: 28215136

Group type: EXPERIMENTAL
Intervention: Systematic prevention and treatment of fever
Number of subjects: 184

Group type: COMPARATOR
Intervention: Standard temperature management
Number of subjects: 184
Study: 25761434

Group type: EXPERIMENTAL
Intervention: Denosumab (60 mg subcutaneously every 6 months)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Oral bisphosphonates
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 42
Study: 24311451

Group type: EXPERIMENTAL
Intervention: Big breakfast (BB) rich in fat and protein providing 33% of total daily energy
Number of subjects: 59

Group type: COMPARATOR
Intervention: Small breakfast (SB) rich in carbohydrates providing 12.5% of total daily energy
Number of subjects: 59
Study: 22445437

Group type: EXPERIMENTAL
Intervention: Contraceptive vaginal ring delivering Nestorone and ethinyl estradiol (EE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral contraceptive containing levonorgestrel and EE
Number of subjects: 0
Study: 19164772

Group type: EXPERIMENTAL
Intervention: Resistance exercise (8 x 5 leg extension, 80% 1 repetition maximum) followed by endurance exercise (30 min cycling, 70% Vo2peak)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Endurance exercise (30 min cycling, 70% Vo2peak) followed by resistance exercise (8 x 5 leg extension, 80% 1 repetition maximum)
Number of subjects: 8
Study: 17721294

Group type: EXPERIMENTAL
Intervention: Systane Lubricant Eye Drops
Number of subjects: 50

Group type: COMPARATOR
Intervention: Refresh Tears
Number of subjects: 50

Group type: COMPARATOR
Intervention: Refresh Endura
Number of subjects: 50
Study: 14969377

Group type: EXPERIMENTAL
Intervention: Tongue Scraping
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Listerine Oral Care Strip
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Saturated Saline Solution
Number of subjects: 60
Study: 15373008

Group type: EXPERIMENTAL
Intervention: Circumferential ankle pressure (CAP) applied using a pediatric blood pressure cuff.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Circumferential ankle pressure (CAP) applied.
Number of subjects: 10
Study: 11159485

Group type: EXPERIMENTAL
Intervention: Prepared strip containing 1.3 microl of 0.5% fluorescein
Number of subjects: 168

Group type: COMPARATOR
Intervention: Standard method of performing the TFI with and without topical anaesthetic
Number of subjects: 168
Study: 9196673

Group type: EXPERIMENTAL
Intervention: Nearpoint condition
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Farpoint condition
Number of subjects: 16
Study: 8195578

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 106

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 106
Study: 2905879

Group type: EXPERIMENTAL
Intervention: Atenolol 25 mg twice daily
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bopindolol 1 mg daily
Number of subjects: 10
Study: 31642513

Group type: EXPERIMENTAL
Intervention: FAUCS
Number of subjects: 112

Group type: COMPARATOR
Intervention: MLC
Number of subjects: 112
Study: 29314597

Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir and dasabuvir regimen (ribavirin-free)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir and dasabuvir + ribavirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir and dasabuvir (ribavirin-free)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genotype 1b patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genotype 1a patients
Number of subjects: 0
Study: 28851789

Group type: EXPERIMENTAL
Intervention: Real stimulation with theta burst stimulation (TBS) of the contralesional primary motor cortex
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 60
Study: 26315876

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (50 mg/kg)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control (rocuronium 0.6 mg/kg)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Ketamine (0.5 mg/kg)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Rocuronium prime (0.06 mg/kg rocuronium 3 minutes before 0.54 mg/kg rocuronium)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Rocuronium 0.9 (0.9 mg/kg)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Rocuronium prime group
Number of subjects: 110
Study: 23219385

Group type: EXPERIMENTAL
Intervention: AZD7009
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 21241263

Group type: EXPERIMENTAL
Intervention: 5 IU of oxytocin during surgical procedure
Number of subjects: 378

Group type: COMPARATOR
Intervention: No oxytocic agent (control group)
Number of subjects: 378
Study: 18278988

Group type: EXPERIMENTAL
Intervention: Acute bilateral electroconvulsive therapy (ECT)
Number of subjects: 489
Study: 17103080

Group type: EXPERIMENTAL
Intervention: Hempseed oil (HO) 30 ml/day for 4 weeks
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Flaxseed oil (FO) 30 ml/day for 4 weeks
Number of subjects: 14
Study: 12924534

Group type: EXPERIMENTAL
Intervention: Nebulized zanamivir (16 mg four times a day) plus rimantadine
Number of subjects: 41

Group type: COMPARATOR
Intervention: Rimantadine with nebulized saline (Control)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Nebulized zanamivir plus rimantadine
Number of subjects: 41
Study: 11070372

Group type: EXPERIMENTAL
Intervention: sipatrigine (10, 18, 27, or 36 mg/kg by continuous intravenous infusion over 65 hours)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: sipatrigine
Number of subjects: 27

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 27
Study: 8622153

Group type: EXPERIMENTAL
Intervention: AVS (4 g, infused intravenously for 6-8 hours once a day for 10 to 14 days)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo (4 g glucose, infused intravenously for 6-8 hours once a day for 10 to 14 days)
Number of subjects: 162
Study: 1567268

Group type: EXPERIMENTAL
Intervention: Gentian violet mouth washes (1.5 ml 0.5% aqueous solution b.i.d.)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Oral ketoconazole (200 mg/day, after a meal)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Nystatin mouth washes (200,000 U oral suspension q.i.d.)
Number of subjects: 141
Study: 4056079

Group type: EXPERIMENTAL
Intervention: Respbid
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Theo-Dur
Number of subjects: 19

Group type: COMPARATOR
Intervention: Intravenous aminophylline
Number of subjects: 19
Study: 31354252

Group type: EXPERIMENTAL
Intervention: Bone-anchored annular closure device (ACD)
Number of subjects: 550

Group type: COMPARATOR
Intervention: No additional implantation (controls)
Number of subjects: 550
Study: 28652064

Group type: EXPERIMENTAL
Intervention: External Focus (EF)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Internal Focus (IF)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Fugl‐Meyer Assessment
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Wolf Motor Function Test
Number of subjects: 33
Study: 27140710

Group type: EXPERIMENTAL
Intervention: somatostatin + ulinastatin
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: somatostatin + gabexate
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: somatostatin + ulinastatin + gabexate
Number of subjects: 492

Group type: COMPARATOR
Intervention: somatostatin
Number of subjects: 492
Study: 24438754

Group type: EXPERIMENTAL
Intervention: Iron supplement of 40 mg/d
Number of subjects: 878

Group type: EXPERIMENTAL
Intervention: Iron supplement of 80 mg/d
Number of subjects: 878

Group type: EXPERIMENTAL
Intervention: Iron supplement of 20 mg/d
Number of subjects: 878

Group type: EXPERIMENTAL
Intervention: Iron supplement of 40 mg/d (Stratum #1)
Number of subjects: 878

Group type: EXPERIMENTAL
Intervention: Iron supplement of 40 mg/d (Stratum #2)
Number of subjects: 878
Study: 22710812

Group type: EXPERIMENTAL
Intervention: Intraoperative infusion of 18 compound amino acids (group AA)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Lactated Ringer solution (group LR)
Number of subjects: 36
Study: 19436119

Group type: EXPERIMENTAL
Intervention: IVIG 2 g/kg for 1 day
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: IVIG 1 g/kg for 1 day
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: IVIG 400 mg/kg/day for 5 days
Number of subjects: 62

Group type: COMPARATOR
Intervention: No IVIG administration
Number of subjects: 62
Study: 17616008

Group type: EXPERIMENTAL
Intervention: PureSorb-Q40 (P40)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lipid-soluble CoQ10
Number of subjects: 0
Study: 15621905

Group type: EXPERIMENTAL
Intervention: Metallic staples
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subcuticular vicryl suture
Number of subjects: 0
Study: 11936563

Group type: EXPERIMENTAL
Intervention: Azimilide 125 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10431402

Group type: EXPERIMENTAL
Intervention: Transurethral electrovaporization of the prostate (TVP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 40
Study: 8771231

Group type: EXPERIMENTAL
Intervention: Cortisol (3 mg/h)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 12
Study: 2170104

Group type: EXPERIMENTAL
Intervention: Instant bean flakes (174 g/d)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Potato flakes (102 g/d)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Instant bean flakes (40 g starch)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Potato flakes (40 g starch)
Number of subjects: 7
Study: 6154562

Group type: EXPERIMENTAL
Intervention: 5% albumin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (HES)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (preinfusion values)
Number of subjects: 0
Study: 6389484

Group type: EXPERIMENTAL
Intervention: Controlled-release theophylline preparation U (Uniphyl tablets) once daily, 800 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controlled-release theophylline T-D (Theo-Dur tablets) administered 12-hourly, 800 mg
Number of subjects: 0
Study: 30303904

Group type: EXPERIMENTAL
Intervention: Nitrous oxide (70% nitrous/30% oxygen)
Number of subjects: 39

Group type: COMPARATOR
Intervention: IV sedation (100 micrograms fentanyl and 2 mg midazolam)
Number of subjects: 39
Study: 26783318

Group type: EXPERIMENTAL
Intervention: Intravenous rt-PA (alteplase)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25303029

Group type: COMPARATOR
Intervention: Viscous fiber blend (VFB) mixed with margarine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Viscous fiber blend (VFB) baked into white bread
Number of subjects: 25

Group type: COMPARATOR
Intervention: Capsules containing VFB
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (no VFB)
Number of subjects: 25